請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77941完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 李財坤(Tsai-Kun Li) | |
| dc.contributor.author | Wan-Ting Tsai | en |
| dc.contributor.author | 蔡菀婷 | zh_TW |
| dc.date.accessioned | 2021-07-11T14:37:54Z | - |
| dc.date.available | 2025-08-16 | |
| dc.date.copyright | 2020-09-07 | |
| dc.date.issued | 2020 | |
| dc.date.submitted | 2020-08-17 | |
| dc.identifier.citation | Austin, C. A., Lee, K. C., Swan, R. L., Khazeem, M. M., Manville, C. M., Cridland, P., . . . Cowell, I. G. (2018). TOP2B: the first thirty years. International journal of molecular sciences, 19(9), 2765. Austin, C. A., Sng, J.-H., Patel, S., Fisher, L. M. (1993). Novel HeLa topoisomerase II is the IIβ isoform: complete coding sequence and homology with other type II topoisomerases. Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression, 1172(3), 283-291. Bailis, J. M., Forsburg, S. L. (2004). MCM proteins: DNA damage, mutagenesis and repair. Current opinion in genetics development, 14(1), 17-21. Been, M. D., Champoux, J. J. (1984). Breakage of single-stranded DNA by eukaryotic type 1 topoisomerase occurs only at regions with the potential for base-pairing. Journal of molecular biology, 180(3), 515-531. Berns, K., Hijmans, E. M., Mullenders, J., Brummelkamp, T. R., Velds, A., Heimerikx, M., . . . Bernards, R. (2004). A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature, 428(6981), 431-437. doi:10.1038/nature02371 Champoux, J. J. (2001). DNA topoisomerases: structure, function, and mechanism. Annual review of biochemistry, 70, 369-413. doi:10.1146/annurev.biochem.70.1.369 Champoux, J. J. (2013). DNA Topoisomerases: Type I. In M. D. L. William J. Lennarz (Ed.), Encyclopedia of Biological Chemistry (Second Edition) (pp. 157-162). Choi, M.-C., Jong, H.-S., Kim, T. Y., Song, S.-H., Lee, D. S., Lee, J. W., . . . Bang, Y.-J. (2004). AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. Oncogene, 23(42), 7095-7103. Colarossi, L., Memeo, L., Colarossi, C., Aiello, E., Iuppa, A., Espina, V., . . . Mueller, C. (2014). Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells. PROTEOMICS–Clinical Applications, 8(11-12), 924-931. Douarre, C., Sourbier, C., Dalla Rosa, I., Das, B. B., Redon, C. E., Zhang, H., . . . Pommier, Y. (2012). Mitochondrial topoisomerase I is critical for mitochondrial integrity and cellular energy metabolism. PloS one, 7(7), e41094. Gray, J., Cubitt, C. L., Zhang, S., Chiappori, A. (2012). Combination of HDAC and topoisomerase inhibitors in small cell lung cancer. Cancer biology therapy, 13(8), 614-622. Gruhn, B., Naumann, T., Gruner, D., Walther, M., Wittig, S., Becker, S., . . . Sonnemann, J. (2013). The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia. Leukemia research, 37(10), 1200-1207. Haberland, M., Montgomery, R. L., Olson, E. N. (2009). The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nature Reviews Genetics, 10(1), 32-42. Haffner, M. C., Aryee, M. J., Toubaji, A., Esopi, D. M., Albadine, R., Gurel, B., . . . Xu, J. (2010). Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nature genetics, 42(8), 668-675. Hanahan, D., Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646-674. doi:10.1016/j.cell.2011.02.013 He, P., Li, K., Li, S.-B., Hu, T.-T., Guan, M., Sun, F.-Y., Liu, W.-W. (2018). Upregulation of AKAP12 with HDAC3 depletion suppresses the progression and migration of colorectal cancer. International journal of oncology, 52(4), 1305-1316. Herman, J. G., Baylin, S. B. (2003). Mechanisms of disease: Gene silencing in cancer in association with promoter hypermethylation. New England Journal of Medicine, 349(21), 2042-2054. doi:DOI 10.1056/NEJMra023075 Ho, L., Crabtree, G. R. (2010). Chromatin remodelling during development. Nature, 463(7280), 474-484. doi:10.1038/nature08911 Hsieh, M. Y., Fan, J. R., Chang, H. W., Chen, H. C., Shen, T. L., Teng, S. C., . . . Li, T. K. (2014). DNA topoisomerase III alpha regulates p53-mediated tumor suppression. Clin Cancer Res, 20(6), 1489-1501. doi:10.1158/1078-0432.CCR-13-1997 Huertas, D., Sendra, R., Munoz, P. (2009). Chromatin dynamics coupled to DNA repair. Epigenetics, 4(1), 31-42. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/19218832 Ju, B.-G., Lunyak, V. V., Perissi, V., Garcia-Bassets, I., Rose, D. W., Glass, C. K., Rosenfeld, M. G. (2006). A topoisomerase IIß-mediated dsDNA break required for regulated transcription. science, 312(5781), 1798-1802. Kim, N., Jinks-Robertson, S. (2017). The Top1 paradox: Friend and foe of the eukaryotic genome. DNA repair, 56, 33-41. Kouzarides, T. (2007). Chromatin modifications and their function. Cell, 128(4), 693-705. doi:10.1016/j.cell.2007.02.005 Liu, Y., He, G., Wang, Y., Guan, X., Pang, X., Zhang, B. (2013). MCM-2 is a therapeutic target of Trichostatin A in colon cancer cells. Toxicology letters, 221(1), 23-30. Luco, R. F., Pan, Q., Tominaga, K., Blencowe, B. J., Pereira-Smith, O. M., Misteli, T. (2010). Regulation of alternative splicing by histone modifications. Science, 327(5968), 996-1000. doi:10.1126/science.1184208 Luo, J., Nikolaev, A. Y., Imai, S.-i., Chen, D., Su, F., Shiloh, A., . . . Gu, W. (2001). Negative control of p53 by Sir2α promotes cell survival under stress. Cell, 107(2), 137-148. Luo, J., Su, F., Chen, D., Shiloh, A., Gu, W. (2000). Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature, 408(6810), 377-381. Morham, S. G., Kluckman, K. D., Voulomanos, N., Smithies, O. (1996). Targeted disruption of the mouse topoisomerase I gene by camptothecin selection. Molecular and cellular biology, 16(12), 6804-6809. Negrini, S., Gorgoulis, V. G., Halazonetis, T. D. (2010). Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol, 11(3), 220-228. doi:10.1038/nrm2858 Ng, S.-W., Liu, Y., Hasselblatt, K. T., Mok, S. C., Berkowitz, R. S. (1999). A new human topoisomerase III that interacts with SGS1 protein. Nucleic acids research, 27(4), 993-1000. Nicholls, T. J., Nadalutti, C. A., Motori, E., Sommerville, E. W., Gorman, G. S., Basu, S., . . . Gustafsson, C. M. (2018). Topoisomerase 3alpha Is Required for Decatenation and Segregation of Human mtDNA. Mol Cell, 69(1), 9-23 e26. doi:10.1016/j.molcel.2017.11.033 Rando, O. J., Chang, H. Y. (2009). Genome-wide views of chromatin structure. Annu Rev Biochem, 78, 245-271. doi:10.1146/annurev.biochem.78.071107.134639 Raynard, S., Bussen, W., Sung, P. (2006). A double Holliday junction dissolvasome comprising BLM, topoisomerase IIIalpha, and BLAP75. J Biol Chem, 281(20), 13861-13864. doi:10.1074/jbc.C600051200 Reed, S. M., Quelle, D. E. (2015). p53 acetylation: regulation and consequences. Cancers, 7(1), 30-69. Spaety, M.-E., Gries, A., Badie, A., Venkatasamy, A., Romain, B., Orvain, C., . . . Mellitzer, G. (2019). HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway. Cancers, 11(11), 1747. Stiborova, M., Eckschlager, T., Poljakova, J., Hrabeta, J., Adam, V., Kizek, R., Frei, E. (2012). The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment. Current medicinal chemistry, 19(25), 4218-4238. Takei, Y., Swietlik, M., Tanoue, A., Tsujimoto, G., Kouzarides, T., Laskey, R. (2001). MCM3AP, a novel acetyltransferase that acetylates replication protein MCM3. EMBO reports, 2(2), 119-123. Tye, B. K. (1999). MCM proteins in DNA replication. Annual review of biochemistry, 68(1), 649-686. Vega, R. B., Matsuda, K., Oh, J., Barbosa, A. C., Yang, X., Meadows, E., . . . Olson, E. N. (2004). Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell, 119(4), 555-566. doi:10.1016/j.cell.2004.10.024 Wang, J. C. (2002). Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol, 3(6), 430-440. doi:10.1038/nrm831 Wang, Y., Lyu, Y. L., Wang, J. C. (2002). Dual localization of human DNA topoisomerase IIIalpha to mitochondria and nucleus. Proc Natl Acad Sci U S A, 99(19), 12114-12119. doi:10.1073/pnas.192449499 West, A. C., Johnstone, R. W. (2014). New and emerging HDAC inhibitors for cancer treatment. The Journal of clinical investigation, 124(1), 30-39. Wilson, A. J., Byun, D. S., Nasser, S., Murray, L. B., Ayyanar, K., Arango, D., . . . Mariadason, J. M. (2008). HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell, 19(10), 4062-4075. doi:10.1091/mbc.E08-02-0139 Yao, T.-P., Seto, E. (2011). Histone deacetylases: the biology and clinical implication (Vol. 206): Springer Science Business Media. Zhang, H., Barceló, J. M., Lee, B., Kohlhagen, G., Zimonjic, D. B., Popescu, N. C., Pommier, Y. (2001). Human mitochondrial topoisomerase I. Proceedings of the National Academy of Sciences, 98(19), 10608-10613. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77941 | - |
| dc.description.abstract | 癌症是經由種種因素的誘導與累積所造成的疾病,基因變異與表觀遺傳變異皆是造成癌症的原因。人類拓樸異構酶作為調控DNA拓樸結構問題的重要一員,是參與DNA 複製、重組及轉錄調節的重要酵素。實驗室先前研究發現,人類第三型拓樸異構酶alpha亞型 (hTop3α)與p53 具有交互關係,並經由蛋白質與啟動子的結合調控,促進p53與p21的表現來抑制腫瘤生成。組織蛋白去乙醯酶是表觀遺傳學中重要的調控因子,透過去乙醯化的酵素功能,可使染色質纏繞變緊密、抑制基因的轉錄表現。組織蛋白去乙醯酶4 (HDAC4)具有調節轉錄及細胞生長的能力,已被證實是p53抑癌途徑的新重要成員,藉由抑制p21進而促進大腸癌的發展。hTop3α與HDAC4在癌症發展中皆扮演著重要角色,故本篇我們想要探討hTop3α和HDAC4在p53介導的腫瘤抑制中的相互作用。首先,透過免疫共沉澱實驗探討hTop3α和HDAC4兩者是否具有交互作用,發現hTop3α可與HDAC4能形成複合體,並從定量即時聚合酶鏈鎖反應結果發現hTop3α缺失會導致HDAC4、p53、p21的基因表現量下降;相反的,當hTop3α過表現時,會使HDAC4、p53、p21的基因、蛋白質表現量上升。此外,我們也藉由軟瓊脂培養基探討hTop3α對腫瘤生成的影響,發現hTop3α缺失會使細胞群落數增加。最後,我們利用p53缺失的細胞進行相關實驗,發現hTop3α對HDAC4的調控並不受p53的影響。此外,hTop3α對p53及HDAC4都有正向的調控,然而p53與HDAC4在p21的表現有不同的影響,從實驗結果可以發現p53帶來的正向調控較HDAC4所帶來的負向調控更為顯著。綜合以上,我們觀察到hTop3α對HDAC4具有正調控,且在p53缺失的細胞中更為顯著。 | zh_TW |
| dc.description.abstract | Cancer is a disease caused by the induction and accumulation of various factors. Both genetic variation and epigenetic variation are the causes of cancer. Human topoisomerases, as an important member of regulating DNA topological problems, are important enzymes involved in DNA replication, recombination and transcriptional regulation. Previous research in our lab found that human topoisomerase III alpha (hTop3α) has physical interaction with p53, which enhances the recruitment of p53 to p21 promoter binding site and promotes the expression of p53 and p21 to inhibit tumorigenesis. Histone deacetylases are important regulatory factor in epigenetics. Through the enzyme function of deacetylation, chromatin structure can be tightened and the transcription performance of genes can be suppressed. Histone deacetylase 4 (HDAC4) has the ability to regulate transcription and cell growth. It has been demonstrated to be a new important member of the p53 tumor suppressor pathway, which promotes the development of colorectal cancer by inhibiting p21. Both hTop3α and HDAC4 play an important role in cancer development, so we want to explore the interaction between hTop3α and HDAC4 in p53-mediated tumor suppression pathway. First, we explored whether the hTop3α and HDAC4 have interaction through co-immunoprecipitation experiment and found that hTop3α can form a complex with HDAC4, thereby may regulate its expression or function. From the quantitative real-time polymerase chain reaction results, we found that hTop3α defect leaded to the decrease gene expression of HDAC4, p53, p21; conversely, when hTop3α was overexpressed, the gene and protein expression of HDAC4, p53, and p21 increased. Furthermore, we explored the effect of hTop3α on tumorigenesis by soft agar assay, and found that the hTop3α defect will increase the colony numbers. We also used p53-deficient cells to perform experiments and found that hTop3α-regulated HDAC4 is p53-independent. In addition, hTop3α can positively regulate p53 and HDAC4, but p53 and HDAC4 have oppositely effects on p21 expression, and the p21 expression showed that the positively regulation by p53 was stronger than the negatively regulation by HDAC4 in hTop3α-mediated manner. In summary, we observed that hTop3α positively regulates HDAC4, and is more significant in p53-deficient cells. | en |
| dc.description.provenance | Made available in DSpace on 2021-07-11T14:37:54Z (GMT). No. of bitstreams: 1 U0001-1608202010061300.pdf: 2596546 bytes, checksum: b7c4f660ff0922480eb60e802e0fd0ac (MD5) Previous issue date: 2020 | en |
| dc.description.tableofcontents | 口試委員審定書 I 致謝 II 中文摘要 III ABSTRACT IV CONTENT VI INTRODUCTION 1 1. DNA topoisomerases 1 1.1 Classification of DNA topoisomerases 1 1.2 Human topoisomerases 2 1.3 Human DNA topoisomerase 3α and its biological functions 3 2. Genomic and Epigenetics 4 2.1 Major epigenetic mechanisms 4 2.2 Histone acetylation and histone deacetylases (HDACs) 6 2.3 Histone deacetylase 4 (HDAC4) and its biological function 7 3. Tumorigenesis 7 3.1 The hallmarks of cancer 8 3.2 Histone deacetylases (HDACs) and tumorigenesis 8 SPECIFIC AIM 10 MATERIALS AND METHODS 11 1. Plasmids and antibodies 11 2. Transfection 11 3. Cell lines and culture conditions 11 4. Lentivirus-based RNA interference 11 5. Quantitative real-time reverse transcription-PCR 12 6. Western blot analysis 13 7. Tumorigenesis assay: anchorage-independent growth on soft agar 13 8. Colony formation assay 14 9. Co-immunoprecipitation 14 10. Chromatin immunoprecipitation (ChIP) assay 14 11. Microarrays analysis 16 12. TCGA RNA-seq data analysis 17 13. Biological function enrichment and pathway analysis 17 Results 19 1. Analyses of p53-dependent or p53-independent pathway in sh-hTop3α HCT116 cells with microarrays. 19 2. Analyses of the different histone deacetylases (HDACs) in sh-hTop3α HCT116 cells and p53 minus HCT116 cells with microarrays. 20 3. The physical interaction between hTop3α and HDAC4. 21 4. Knockdown of hTop3α reduced HDAC4 mRNA expression in HCT116 cells. 21 5. hTop3α knockdown enhanced tumorigenesis ability in HCT116 cells. 22 6. Ectopic expression of hTop3α increased HDAC4, p53, p21 expression in HCT116 cells. 23 7. The hTop3α-induced HDAC4 expression regulation was p53-independent.. 23 8. Knockdown of HDAC4 enhanced the specific binding of hTop3α and p53 to p21 promoter. 24 DISCUSSION 26 FIGURES AND TABLES 30 Figure 1. Analyses of p53-dependent or p53-independent pathway in sh-hTop3α HCT116 cells with microarrays. 31 Figure 2. Analyses of the different histone deacetylases (HDACs) in sh-hTop3α HCT116 cells and p53 minus HCT116 cells with microarrays. 32 Figure 3. hTop3α and HDAC4 had physical interaction. 34 Figure 4. Knockdown of hTop3α reduced HDAC4 expression in HCT116 cells. 35 Figure 5. hTop3α knockdown enhanced tumorigenesis ability in HCT116 cells. 37 Figure 6. Ectopic expression of hTop3α increased HDAC4, p53, p21 expression in HCT116 cells. 38 Figure 7. The regulation of HDAC4 expression by hTop3α was p53-independent. 42 Figure 8. Knockdown of HDAC4 enhanced the specific binding of hTop3α and p53 to p21 promoter. 44 Table 1. Reactome pathway analysis of hTop3α-dependent but p53-independent genes. 46 Figure 9. Analysis of differential genes expression in HDAC4 high compared with HDAC4 low patients in TCGA colon adenocarcinoma (COAD) RNAseq data. 47 Table 2. GO pathway analysis of the genes affected by high HDAC4 expression in TCGA COAD RNAseq. 48 References 49 | |
| dc.language.iso | en | |
| dc.subject | HDAC4 | zh_TW |
| dc.subject | 腫瘤新生 | zh_TW |
| dc.subject | p21 | zh_TW |
| dc.subject | p53 | zh_TW |
| dc.subject | hTop3α | zh_TW |
| dc.subject | p53 | en |
| dc.subject | human topoisomerase IIIα (hTop3α) | en |
| dc.subject | p21 | en |
| dc.subject | tumorigenesis | en |
| dc.subject | histone deacetylase 4 (HDAC4) | en |
| dc.title | 探討第三型拓樸異構酶α亞型與HDAC4在p53介導的腫瘤抑制中的交互作用 | zh_TW |
| dc.title | Investigation of the interaction between human topoisomerase IIIα and HDAC4 on p53-mediated tumor suppression | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 108-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 蔡幸真(Hsing-Chen Tsai),詹迺立(Nei-Li Chan) | |
| dc.subject.keyword | hTop3α,HDAC4,p53,p21,腫瘤新生, | zh_TW |
| dc.subject.keyword | human topoisomerase IIIα (hTop3α),histone deacetylase 4 (HDAC4),p53,p21,tumorigenesis, | en |
| dc.relation.page | 52 | |
| dc.identifier.doi | 10.6342/NTU202003565 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2020-08-17 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 微生物學研究所 | zh_TW |
| dc.date.embargo-lift | 2025-08-16 | - |
| 顯示於系所單位: | 微生物學科所 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-1608202010061300.pdf 未授權公開取用 | 2.54 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
